Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IGC PharmaIGC +5.05%27 Equity-to-Asset is 0.67 as of Mar. 2026, which is 20% below its 10-year median of 0.84. GuruFocus rates IGC with a GF Score™ of 27/100 and a GF Value™ of $0.22 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,415 Biotechnology companies, IGC Pharma ranks worse than 50.88% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. IGC Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $6.12 Mil. IGC Pharma's Total Assets for the quarter that ended in Mar. 2026 was $9.19 Mil.
Therefore, IGC Pharma's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.67.
The historical rank and industry rank for IGC Pharma's Equity-to-Asset or its related term are showing as below:
IGC'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.62 Med: 0.84 Max: 0.98
Current: 0.67
During the past 13 years, the highest Equity to Asset Ratio of IGC Pharma was 0.98. The lowest was 0.62. And the median was 0.84.
IGC's Equity-to-Asset is ranked worse than 50.88% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs IGC: 0.67
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
IGC Pharma Equity-to-Asset Related Terms
IGC Pharma Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for IGC Pharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC vs ATNM, ACTU, KYNB: Equity-to-Asset Comparison
For the Biotechnology subindustry, IGC Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGC Pharma Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGC Pharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where IGC Pharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
IGC Pharma's Equity to Asset Ratio for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC Pharma (IGC) has a Equity-to-Asset of 0.67 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on IGC Pharma and its competitors. This is 20% below median its historical median of 0.84. Over the past decade, IGC Pharma's Equity-to-Asset has ranged from 0.62 to 0.98. According to the industry distribution chart, IGC Pharma ranks #720 out of 1415 companies in the Biotechnology industry, placing it in the top 50.9%.
Is IGC Pharma's Equity-to-Asset too high?
IGC Pharma's current Equity-to-Asset of 0.67 is 20% below median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 0.98. The Biotechnology industry median Equity-to-Asset is 0.68. IGC Pharma's value of 0.67 is 1.5% below this industry median. Based on the distribution chart, IGC Pharma ranks #720 out of 1415 companies in the Biotechnology industry, which is below the industry midpoint. Overall, IGC Pharma has a GF Score™ of 27/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's Equity-to-Asset compare to ATNM and ACTU?
According to the Biotechnology industry distribution chart, IGC Pharma ranks #720 out of 1415 companies for Equity-to-Asset. This places IGC Pharma in the lower half of its industry. The industry median Equity-to-Asset is 0.68. IGC Pharma's value of 0.67 is 1.5% below this benchmark. Historically, IGC Pharma's own Equity-to-Asset has ranged from 0.62 to 0.98 over the past decade. While the company's 10-year median is 0.84 vs. the industry median of 0.68, IGC Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IGC Pharma's current Equity-to-Asset of 0.67 is 1.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on IGC Pharma and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IGC Pharma's current Equity-to-Asset is 0.67, which is 20% below median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.22, compared to a current price of $0.28 — trading 27.7% above its estimated fair value. The current Equity-to-Asset is 0.67, which is 20% below median its 10-year median of 0.84 and 1.5% below the Biotechnology industry median of 0.68. IGC Pharma's overall GF Score™ is 27/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For IGC Pharma (IGC), the current Equity-to-Asset is 0.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IGC Pharma (IGC) Overvalued in 2026?
Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued.
The current stock price of $0.28 is trading 27.7% above its estimated GF Value™ of $0.22.
GuruFocus considers IGC Pharma to be Modestly Overvalued.
Key valuation signals for IGC:
Equity-to-Asset: 0.67 (20% below median its 10-year median of 0.84)
GF Value™: $0.22 vs. price of $0.28 (27.7% above fair value)
Industry Position: 1.5% below the Biotechnology median (#720 of 1415)
No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
27GF Score
Get the complete analysis for IGC
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IGC has been successfully added to your 
